Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (GB:0L35)
LSE:0L35
0L35 Stock Chart & Stats
$22.46
$2.06(1.65%)
At close: 4:00 PM EST
$22.46
$2.06(1.65%)
Day’s Range― - ―
52-Week Range$10.49 - $138.41
Previous CloseN/A
Volume776.00
Average Volume (3M)37.10K
Market Cap
$2.20B
Enterprise Value$2.38B
Total Cash (Recent Filing)$800.14M
Total Debt (Recent Filing)$1.35B
Price to Earnings (P/E)20.9
Beta1.66
Next Earnings
Oct 29, 2025EPS Estimate
-0.7Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding97,713,440
10 Day Avg. Volume46,428
30 Day Avg. Volume37,104
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit1.21
Enterprise Value/Ebitda54.06
Forecast
1Y Price Target
$23.27Price Target Upside3.61% Upside
Rating ConsensusHold
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
Biotechnology AdvancementsAnalysts view Sarepta Therapeutics as well-positioned to benefit from advancements in biotechnology and medical innovation.
Gene Therapy InnovationSarepta Therapeutics Inc. is gaining attention due to its focus on gene therapy, which is considered a promising field in medical innovation.
Product Uptake And Market ConfidenceSRPT's current valuation renders its risk/reward skewed to the upside given that Elevidys uptake is ramping up and sales could beat expectations.
Bears Say
Market UncertaintyThe cancellation of the R&D Day and uncertainty about the timing of data disclosure make it difficult to gain excitement or confidence ahead of the preliminary data.
Safety ConcernsSarepta Therapeutics announced a second non-ambulatory Elevidys patient died from acute liver failure, leading to the suspension of all Elevidys shipments for non-ambulatory DMD patients.
Safety Concerns And Product RisksThe potential death of an ambulatory Elevidys patient remains the biggest risk, which could trigger concerns about the market removal of Elevidys.
Sarepta Therapeutics News
0L35 FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest share price was $10.48 and its highest was $138.41 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.20B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 10 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 06, 2025. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $0.832 by $1.058.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Sarepta Therapeutics dividends here
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,713,440 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.89 in its last earnings report, beating expectations of $0.832. Following the earnings report the stock price went up 6.502%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in GB:0L35
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.27 (3.61% Upside)
$23.27 (3.61% Upside)
Blogger Sentiment
Bullish
GB:0L35 Sentiment 62%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.88%
12-Months-Change
Fundamentals
Return on Equity
-4.76%
Trailing 12-Months
Asset Growth
7.46%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
0L35 Stock 12 Month Forecast
Average Price Target
$23.27
▲(3.61% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Options Prices
Currently, No data available
---